Molbio Diagnostics IPO is a book-built issue worth ₹939.70 crores, comprising a fresh issue of 0.25 crore shares aggregating to ₹200.00 crores and an offer for sale of 0.92 crore shares aggregating to ₹739.70 crores.
The IPO will open for subscription on Aug 10, 2026 and close on Aug 12, 2026. The allotment is expected to be finalised on Aug 13, 2026, while the shares are proposed to be listed on the NSE and BSE on Aug 17, 2026.
The price band has been fixed at ₹768 to ₹807 per share, with a lot size of 18 shares. Retail investors need a minimum investment of ₹14,526 (18 shares), calculated at the upper price band. Kotak Mahindra Capital Co. Ltd. is the book-running lead manager, and Kfin Technologies Ltd. is the registrar to the issue.
For detailed information on the company’s business, financials, risk factors, and the proposed utilisation of proceeds, investors should refer to the Moblio Diagnostics IPO Red Herring Prospectus(RHP) before making an investment decision.
Company Overview
Molbio Diagnostics Limited is an Indian molecular diagnostics company focused on developing and manufacturing rapid, point-of-care diagnostic solutions. The company offers integrated diagnostic platforms, testing kits, reagents, and software that enable the quick detection of infectious diseases and other medical conditions, making advanced diagnostics accessible even in resource-limited settings.
Its flagship Truenat® platform is a portable, chip-based real-time PCR system designed to deliver accurate test results within a short time. The platform supports testing for a wide range of diseases, including tuberculosis (TB), COVID-19, hepatitis, HPV, dengue, malaria, HIV, and several other infectious diseases.
The company has built end-to-end capabilities across research and development, product design, manufacturing, and commercialization. Its products are used by hospitals, diagnostic laboratories, public health institutions, and government healthcare programs in India and international markets.
Molbio Diagnostics focuses on innovation-driven healthcare solutions, supported by a broad test menu, strong R&D capabilities, and a growing global distribution network. The company aims to improve access to reliable molecular diagnostics through affordable, portable, and easy-to-use testing technologies.
IPO Details
| Particulars | Details |
|---|---|
| IPO Date | 10 to 12 August, 2026 |
| Allotment | Thursday, August 13, 2026 |
| Listing Date | Monday, August 17, 2026 |
| Face Value | ₹1 per share |
| Price Band | ₹768 to ₹807 per share |
| Lot Size | 18 Shares |
| Issue Type | Book Building IPO |
| Sale Type | Fresh capital cum OFS |
| Total Issue Size | 1,16,46,246 shares (agg. up to ₹940 Cr) |
| Fresh Issue | 24,80,246 shares (agg. up to ₹200 Cr) |
| Offer for Sale (OFS) | 91,66,000 shares of ₹1 (agg. up to ₹740 Cr) |
| Shareholding Pre-Issue | 11,27,59,750 shares |
| Shareholding Post-Issue | 11,52,39,996 shares |
| Listing Exchange | BSE, NSE |
(Compiled from RHP and market updates)
Industry Context
- India’s diagnostics market was valued at ₹ 1,354.2 billion (USD 15.3 billion) in Fiscal 2026, with the in vitro diagnostics (IVD) segment accounting for 56.1% of the total market. The market is projected to reach ₹ 2,356.5 billion (USD 26.6 billion) by Fiscal 2031, growing at a CAGR of 11.7%.
- The diagnostics market expanded from ₹ 725.8 billion (USD 10.31 billion) in Fiscal 2021 to ₹ 1,354.2 billion (USD 15.3 billion) in Fiscal 2026, registering a CAGR of 13.3%. Growth is supported by the rising burden of chronic diseases, increasing preventive healthcare awareness, an ageing population, and government healthcare initiatives.
- The IVD market, valued at ₹ 760.5 billion (USD 8.6 billion) in Fiscal 2026, comprises immunodiagnostics, haematology, molecular diagnostics, clinical chemistry, and other diagnostic techniques. Among these, clinical chemistry holds the largest share at 31.0%, with a market size of ₹ 235.7 billion (USD 2.6 billion), followed by immunodiagnostics at ₹ 178.7 billion (USD 2.0 billion).
- Based on products, the IVD industry includes reagents, instruments/devices, and diagnostic software. These products support testing, sample analysis, data management, and result interpretation across laboratories, hospitals, and healthcare facilities.
- Most diagnostic testing in India remains illness-focused, with only approximately 10% of tests related to wellness and preventive healthcare. At the same time, molecular diagnostics is gaining importance for the early detection and monitoring of infectious diseases, genetic disorders, and non-communicable diseases.
Business Strengths
- The company’s Truenat platform provides rapid, point-of-care molecular testing and includes WHO-endorsed technology for tuberculosis diagnosis, strengthening its credibility and adoption across healthcare systems.
- Molbio Diagnostics continuously invests in innovation, supported by an extensive global patent portfolio that helps develop new diagnostic solutions and strengthens its competitive position.
- The company generates recurring income through the sale of diagnostic test kits and consumables used with its installed diagnostic systems, supporting long-term revenue growth.
- Molbio Diagnostics operates in more than 90 countries, serving governments, public health agencies, hospitals, and diagnostic laboratories through long-standing customer relationships.
- The company expands its product portfolio and market reach through acquisitions, collaborations, and partnerships that enhance its capabilities in molecular diagnostics and healthcare.
- The management team brings extensive experience in molecular diagnostics, medical technology, and healthcare innovation, supporting product development, operational execution, and long-term growth.
Business Risks
- A significant share of the company’s revenue comes from government agencies and public healthcare programs. Any reduction in funding, policy changes, or delays in procurement could affect business performance.
- A substantial portion of revenue is generated from the Truenat diagnostic platform. Lower demand, technological disruptions, or product-related issues could impact the company’s financial performance.
- The molecular diagnostics industry is competitive, with global and domestic players introducing new technologies. Failure to keep pace with innovation may affect market share.
- The company operates in a highly regulated industry where product approvals, quality standards, and compliance requirements vary across countries. Delays or non-compliance could impact product launches and sales.
- Sustaining growth requires ongoing investment in research and development. Delays in developing new products or unsuccessful innovation efforts could reduce the company’s competitive advantage.
- With operations across multiple international markets, the company faces risks related to supply chain disruptions, geopolitical developments, foreign exchange fluctuations, and changing trade regulations.
Financial Performance
Molbio Diagnostics Limited – Financials (₹ in Million)
| Particulars | Fiscal 2026 | Fiscal 2025 | Fiscal 2024 |
|---|---|---|---|
| Revenue from Operations | 14,456.87 | 10,204.18 | 8,365.61 |
| Total Liabilities | 8,396.48 | 4,942.70 | 3,922.19 |
| EBITDA | 3,282.43 | 2,566.39 | 1,850.93 |
| EBITDA Margin (%) | 22.56% | 24.97% | 22.02% |
| Profit After Tax (PAT) | 1,641.40 | 1,385.79 | 835.42 |
| Return on Equity (ROE) | 15.59% | 16.20% | 13.20% |
| Return on Capital Employed (ROCE %) | 17.55% | 20.98% | 15.80% |
(Source: RHP)
Key Ratios & Metrics
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Return on Equity (ROE) | 15.59% | 16.20% |
| Return on Capital Employed (ROCE) | 17.55% | 20.98% |
| Return on Net Worth (RoNW) | 14.55% | 15.23% |
| PAT Margin | 11.28% | 13.48% |
| EBITDA Margin | 22.56% | 24.97% |
| Net Asset Value (NAV per share) | ₹101.51 | ₹84.51 |
(Source: RHP)
Objects of the Offer
- Establishing a research and development facility and a Centre of Excellence, along with office infrastructure for the company, its subsidiaries, and associate entities.
- Funding the purchase of plant, machinery, and other equipment for the company’s manufacturing units in Goa Unit I, Goa Unit II, and Visakhapatnam Unit.
- Meeting general corporate purposes.
Conclusion
Molbio Diagnostics Limited operates in the fast-growing molecular diagnostics industry with a strong focus on innovation, rapid disease detection, and point-of-care testing. Its proprietary Truenat platform, expanding global footprint, and investments in research and manufacturing strengthen its long-term growth prospects.
The proposed IPO proceeds are expected to support capacity expansion and product development, further enhancing the company’s competitive position. However, investors should also consider risks such as regulatory requirements, dependence on government procurement, and intense competition in the diagnostics market before making an investment decision.
Overall, investors should evaluate the company’s business model, financial performance, industry outlook, competitive positioning, valuation, and risk factors in detail, and carefully review the Red Herring Prospectus (RHP) before making an informed investment decision.
If you are considering participating in upcoming IPOs, you can apply for IPOs with ease on Paytm Money and track allotments, listings, and other key updates in one place.
Disclaimer: Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. This content is purely for informational purposes only and should not be considered as investment advice or a recommendation. Securities quoted are for illustration purposes only and not recommendatory. Investors are requested to do their own due diligence before investing.
Paytm Money Ltd. SEBI Reg. No. Broking – INZ000240532; Depository Participant – IN – DP – 416 – 2019, Depository Participant Number: CDSL – 12088800. Trading and clearing member of NSE (90165, M52073), BSE (6707), MCX (57525), NCDEX (1315, M51110), and MSEI (85300). SEBI Reg. No. Research Analyst – INH000020086. Regd. Office: 136, 1st Floor, Devika Tower, Nehru Place, Delhi – 110019. For complete Terms & Conditions and Disclaimers visit: https://www.paytmmoney.com/stocks/policies/terms
